Proudman RG[au] - Search Results

Year	Number of Results
2008	1
2011	1
2013	1
2014	2
2015	1
2020	1
2021	1
2022	3
2023	1

1

The selectivity of α-adrenoceptor agonists for the human α1A, α1B, and α1D-adrenoceptors.

Proudman RGW, Baker JG. Proudman RGW, et al. Pharmacol Res Perspect. 2021 Aug;9(4):e00799. doi: 10.1002/prp2.799. Pharmacol Res Perspect. 2021. PMID: 34355529 Free PMC article.

2

The signaling and selectivity of α-adrenoceptor agonists for the human α2A, α2B and α2C-adrenoceptors and comparison with human α1 and β-adrenoceptors.

Proudman RGW, Akinaga J, Baker JG. Proudman RGW, et al. Pharmacol Res Perspect. 2022 Oct;10(5):e01003. doi: 10.1002/prp2.1003. Pharmacol Res Perspect. 2022. PMID: 36101495 Free PMC article.

3

The affinity and selectivity of α-adrenoceptor antagonists, antidepressants and antipsychotics for the human α2A, α2B, and α2C-adrenoceptors and comparison with human α1 and β-adrenoceptors.

Proudman RGW, Akinaga J, Baker JG. Proudman RGW, et al. Pharmacol Res Perspect. 2022 Apr;10(2):e00936. doi: 10.1002/prp2.936. Pharmacol Res Perspect. 2022. PMID: 35224877 Free PMC article.

4

The affinity and selectivity of α-adrenoceptor antagonists, antidepressants, and antipsychotics for the human α1A, α1B, and α1D-adrenoceptors.

Proudman RGW, Pupo AS, Baker JG. Proudman RGW, et al. Pharmacol Res Perspect. 2020 Aug;8(4):e00602. doi: 10.1002/prp2.602. Pharmacol Res Perspect. 2020. PMID: 32608144 Free PMC article.

5

Impact of polymorphic variants on the molecular pharmacology of the two-agonist conformations of the human β1-adrenoceptor.

Baker JG, Proudman RG, Hill SJ. Baker JG, et al. Among authors: proudman rg. PLoS One. 2013 Nov 8;8(11):e77582. doi: 10.1371/journal.pone.0077582. eCollection 2013. PLoS One. 2013. PMID: 24250787 Free PMC article.

6

The Isoleucine at Position 118 in Transmembrane 2 Is Responsible for the Selectivity of Xamoterol, Nebivolol, and ICI89406 for the Human β1-Adrenoceptor.

Lim VJY, Proudman RGW, Monteleone S, Kolb P, Baker JG. Lim VJY, et al. Among authors: proudman rgw. Mol Pharmacol. 2023 Feb;103(2):89-99. doi: 10.1124/molpharm.122.000583. Epub 2022 Nov 9. Mol Pharmacol. 2023. PMID: 36351797

7

Salmeterol's extreme β2 selectivity is due to residues in both extracellular loops and transmembrane domains.

Baker JG, Proudman RG, Hill SJ. Baker JG, et al. Among authors: proudman rg. Mol Pharmacol. 2015 Jan;87(1):103-20. doi: 10.1124/mol.114.095364. Epub 2014 Oct 16. Mol Pharmacol. 2015. PMID: 25324048

8

Identification of key residues in transmembrane 4 responsible for the secondary, low-affinity conformation of the human β1-adrenoceptor.

Baker JG, Proudman RG, Hill SJ. Baker JG, et al. Among authors: proudman rg. Mol Pharmacol. 2014 May;85(5):811-29. doi: 10.1124/mol.114.091587. Epub 2014 Mar 7. Mol Pharmacol. 2014. PMID: 24608857 Free PMC article.

9

Role of key transmembrane residues in agonist and antagonist actions at the two conformations of the human beta1-adrenoceptor.

Baker JG, Proudman RG, Hawley NC, Fischer PM, Hill SJ. Baker JG, et al. Among authors: proudman rg. Mol Pharmacol. 2008 Nov;74(5):1246-60. doi: 10.1124/mol.108.048371. Epub 2008 Aug 7. Mol Pharmacol. 2008. PMID: 18687809

10

The pharmacological effects of the thermostabilising (m23) mutations and intra and extracellular (β36) deletions essential for crystallisation of the turkey β-adrenoceptor.

Baker JG, Proudman RG, Tate CG. Baker JG, et al. Among authors: proudman rg. Naunyn Schmiedebergs Arch Pharmacol. 2011 Jul;384(1):71-91. doi: 10.1007/s00210-011-0648-4. Epub 2011 May 6. Naunyn Schmiedebergs Arch Pharmacol. 2011. PMID: 21547538 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results